Abu Dhabi:ADCAN Pharma, a pharmaceutical manufacturer based in the UAE, and MS Pharma, a leading regional biopharmaceutical company, have announced a strategic collaboration to enhance the localization of biosimilars and other pharmaceutical products in the United Arab Emirates. This partnership was revealed at the Abu Dhabi Future Health Summit, emphasizing the companies' commitment to strengthening regional pharmaceutical manufacturing capabilities, improving the affordability and accessibility of high-quality medicines, and ensuring a more consistent supply across the region.
According to Emirates News Agency, the collaboration sets a framework for local manufacturing, packaging, testing, and batch release of biosimilars, injectable medicines, and oral solid dosage forms in the UAE. There is a particular focus on biosimilars, underlining the growing importance of advanced biologic therapies in treating complex and chronic diseases. The proposed portfolio addresses therapeutic areas such as oncology, immunology, ophthalmology, respiratory diseases, metabolic and musculoskeletal conditions, as well as anti-infectives, cardiovascular, neurological, and genitourinary care.
Dr. Fokion Sinis, CEO of ADCAN Pharma, remarked that the partnership with MS Pharma represents a significant step in advancing pharmaceutical localization in the UAE. The collaboration will allow ADCAN to establish a laboratory in the UAE capable of conducting comprehensive quality testing for monoclonal antibodies, marking a milestone in building biosimilars technology and testing capabilities within the country. This initiative, combined with MS Pharma's biopharmaceutical expertise, is expected to lay the groundwork for a sustainable biologics ecosystem that enhances the UAE's healthcare resilience and positions the nation as a regional leader in advanced pharmaceutical manufacturing.
Ghandi Yacoub, VP Commercial at MS Pharma, highlighted that expanding access to high-quality, advanced treatments is central to MS Pharma's mission to improve the quality of life for communities across the region. The company's growing biosimilar portfolio and biopharmaceutical expertise are key to addressing unmet medical needs and broadening treatment options. By leveraging ADCAN's established manufacturing infrastructure and local capabilities, the partnership aims to bring treatments closer to patients and support more sustainable healthcare systems throughout the region.
The collaboration aims to progressively expand local capabilities, improve patient access, and contribute to a more resilient and sustainable pharmaceutical sector. This aligns with the UAE's healthcare and industrial development priorities to advance pharmaceutical localization, strengthen domestic manufacturing capabilities, and enhance the competitiveness of UAE-manufactured pharmaceutical products in regional and global markets.